Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR

Slides:



Advertisements
Similar presentations
HnRNP L and HnRNP A1 Induce Extended U1 snRNA Interactions with an Exon to Repress Spliceosome Assembly Ni-Ting Chiou, Ganesh Shankarling, Kristen W. Lynch.
Advertisements

Luke A. Gilbert, Max A. Horlbeck, Britt Adamson, Jacqueline E
“CRISPR genome editing” Precise gene regulation/modification using the simple CRISPR/Cas9 system Thank you. Nucleeases will be used as a new tool that.
CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells Presented by Nur Ata Bruss and Xinyi Ma.
Specificity of RNAi and genome editing
Genome editing to breed better plants
Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
RNAi Overview
Lecture – FALL 2017 Modern methods in Molecular Biology
Expanding the Biologist’s Toolkit with CRISPR-Cas9
Dieter Steinmetz Universität Tübingen – ZMBP Kurs WS 15/16
CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity
RNAi Delivers Insights into Liver Cancer
Rewiring Cas9 to Target New PAM Sequences
Boxuan Simen Zhao, Chuan He  Molecular Cell 
Methed-Up FOXOs Can't In-Akt-ivate
Relationship between Genotype and Phenotype
Molecular Therapy - Nucleic Acids
How To Choose a Good Scientific Problem
Correction of a Genetic Disease in Mouse via Use of CRISPR-Cas9
Astrid Breitbart, Charles E. Murry  Cell Stem Cell 
P Bodies and the Control of mRNA Translation and Degradation
Gaelen T. Hess, Josh Tycko, David Yao, Michael C. Bassik 
CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity
Research Techniques Made Simple: The Application of CRISPR-Cas9 and Genome Editing in Investigative Dermatology  Joan Ramon Guitart, Jodi L. Johnson,
Mouse Genome Engineering via CRISPR-Cas9 for Study of Immune Function
Nicolas Erard, Simon R.V. Knott, Gregory J. Hannon  Molecular Cell 
Feasibility of new breeding techniques for organic farming
Eukaryotic Transcription Activation: Right on Target
Astrid Breitbart, Charles E. Murry  Cell Stem Cell 
Molecular Therapy - Nucleic Acids
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
Therapeutic editing of hepatocyte genome in vivo
USH2A Gene Editing Using the CRISPR System
CRISPR genome-editing: A medical revolution
Double Repression in Jasmonate-Mediated Plant Defense
Working in the Post-Genomic C. elegans World
Alex M. Plocik, Brenton R. Graveley  Molecular Cell 
Volume 21, Issue 3, Pages (February 2006)
Volume 154, Issue 6, Pages (September 2013)
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Nicholas D Weber, Daniel Stone, Keith R Jerome  Molecular Therapy 
Toward Whole-Transcriptome Editing with CRISPR-Cas9
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Aging: A Sirtuin Shake-Up?
Gang Wang, Na Zhao, Ben Berkhout, Atze T Das  Molecular Therapy 
Advances in Industrial Biotechnology Using CRISPR-Cas Systems
Nuclear Decay Factors Crack Up mRNA
Boxuan Simen Zhao, Chuan He  Molecular Cell 
A Hormone Sends Instant Messages to the Genome
CRISPR-Mediated Base Editing without DNA Double-Strand Breaks
Volume 49, Issue 1, Pages 1-3 (January 2013)
A CRISPR Approach to Gene Targeting
William T. Hendriks, Curtis R. Warren, Chad A. Cowan  Cell Stem Cell 
Molecular Therapy - Nucleic Acids
Functional Enhancer Screening in Single Cells
Volume 25, Issue 2, Pages (February 2017)
Andres Canela, Andre Stanlie, André Nussenzweig  Molecular Cell 
Dan Yu, Rongdiao Liu, Geng Yang, Qiang Zhou  Cell Reports 
Natalay Kouprina, Vladimir Larionov 
CRISPR/Cas9: Transcending the Reality of Genome Editing
Silencing the Transcriptome's Dark Matter: Mechanisms for Suppressing Translation of Intergenic Transcripts  Kellie S. Bickel, David R. Morris  Molecular.
Steven West, Nicholas J. Proudfoot, Michael J. Dye  Molecular Cell 
RNAi screening formats.
How To Choose a Good Scientific Problem
Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off- target Effects in Genome Editing  Ciaran M Lee, Thomas J Cradick,
CRISPR in Parasitology: Not Exactly Cut and Dried!
CRISPR Craze to Transform Cardiac Biology
Presentation transcript:

Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR Michael Boettcher, Michael T. McManus  Molecular Cell  Volume 58, Issue 4, Pages 575-585 (May 2015) DOI: 10.1016/j.molcel.2015.04.028 Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 1 Mechanisms of Action of RNAi and TALE/N (A) RNAi degrades transcripts post-transcriptionally in the cytoplasm. (B) TALE repression prevents transcription when targeted to the TSS. (C) Dimerized TALENs induce a site-specific DSB that is repaired via error-prone NHEJ, potentially leading to frameshift mutations when exons are targeted. Molecular Cell 2015 58, 575-585DOI: (10.1016/j.molcel.2015.04.028) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 2 Mechanisms of Action of CRISPR-Based Technologies (A) Cas9 nuclease monomer is guided to its target site via sgRNA and induces a site-specific DSB that is repaired via error-prone NHEJ, potentially leading to frameshift mutations when exons are targeted. (B) CRISPRi prevents transcription when targeted to the TSS. (C) CRISPRa activates transcription when targeted to the TSS. Molecular Cell 2015 58, 575-585DOI: (10.1016/j.molcel.2015.04.028) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 3 User Guide Decision Tree for Help to Choose the Right Tool (1) Known sequence. For your targeted organism, what type of known sequence information is available? Transcriptome sequence alone allows the targeting of mRNA (si/shRNAs) and DNA exons (TALENs and Cas9 nuclease). If your organism’s genome has been sequenced and TSSs have been annotated, all technologies become available, since TALE repression and CRISPRi/a target promoter regions. (2) Loss-of-function-phenotype. What type of loss-of-function phenotype do you want? While RNAi, TALE-repression, and CRISPRi induce reversible gene knockdown, TALEN and Cas9 nuclease induce a permanent knockout. (3) Time to phenotype. How long will it take from the initial planning of the experiment to finally having a loss-of-function phenotype in cells? Transfection of siRNAs remains the most direct and quickest route. For RNAi using shRNAs as well as CRISPRi/a and Cas9 nuclease, appropriate shRNA/sgRNA plasmids need to be cloned. Moreover, it may be necessary to validate the functionality of Cas9 in target cells. The most time consuming way to induce loss-of-function is TALENs, since each target site requires the design of a specific amino acid sequence of the TALEN DBD. (4) Type of phenotype. RNAi, TALE repression, and CRISPRi/a are best suited to generate hypomorphic phenotypes that mimic for instance the inhibition of a target by a drug. TALEN and Cas9 nuclease on the other hand can generate complete knockout phenotypes (null allele) via genome editing. (5) Cost of experiment. How much will the production of required reagents cost? shRNAs and sgRNAs are generated by simple cloning or they can be purchased. Because TALEN-based technologies require a more complicated synthesis, cloning them or purchasing them generally costs more. Performing RNAi via siRNAs requires the costly synthesis of short RNAs. (6) Ease of experiment. How much relative effort does it take until one arrives at the desired loss-of-function phenotype? RNAi via siRNAs necessitates only the purchase or synthesis of short RNAs, followed by a simple transfection into target cells. RNAi via shRNAs and CRISPR-based approaches additionally involve the cloning of shRNAs or sgRNAs. The design and cloning of TALEN-based technologies are relatively more complicated, making it less easy to use. (7) Off-targeting. How severe are the known off-target effects? So far, the described off-target effects for CRISPR as well as TALEN technology appear to be less of an issue compared to RNAi. While off-targeting of an si/shRNA to a given RNA can result in an undesired phenotype, it seems likely that TALEN and CRISPR off-targeting to the genomic DNA may not often produce an undesired phenotype. Molecular Cell 2015 58, 575-585DOI: (10.1016/j.molcel.2015.04.028) Copyright © 2015 Elsevier Inc. Terms and Conditions